Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy
Further Publications Urology
Related content
Uro-Oncology
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Eur Urol
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR
doi: 10.1016/j.eururo.2024.03.036
Uro-Oncology
Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies
Prostate Cancer Prostatic Dis
Falagario UG, Pellegrino F, Fanelli A, Guzzi F, Bartoletti R, Cash H, Pavlovich C, Emberton M, Carrieri G, Giannarini G
doi: 10.1038/s41391-024-00827-x
Benign Prostatic Hyperplasia (BPH)
Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
Prostate
Jirásko M, Viták R, Pecen L, Pinkeová A, Tkáč J, Bertók T, Bergman N, Kučera R
doi: 10.1002/pros.24801
COMMENTED
Uro-Oncology
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV
doi: 10.1001/jamaoncol.2025.0110
Uro-Oncology
Androgen Deprivation Therapy and Newly Developed Neovascular Age-Related Macular Degeneration Risk in Patients with Prostate Cancer
J Clin Med
Ha JS, Kim DK, Lee HS, Jeon S, Jeon J, Kim D, Kim JS, Kim B, Kim M, Cho KS
doi: 10.3390/jcm13102978
Uro-Oncology
The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study
Prostate
Massanova M, Barone B, Caputo VF, Napolitano L, Ponsiglione A, Del Giudice F, Ferro M, Lucarelli G, Lasorsa F, Busetto GM, Robertson S, Trama F, Imbimbo C, Crocetto F
doi: 10.1002/pros.24761
Further Publications Urology
The 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH
BJU Int
Brown N, Kiosoglous A, Castree S, Firouzmand S, McBean R, Walker DG, Wallace S, Kua B, Gianduzzo T, Esler RC, Campbell P, Schoeman J, Yaxley J
doi: 10.1111/bju.16479
Uro-Oncology
Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial
J Urol
Bahler CD, Tachibana I, Tann M, Collins K, Swensson JK, Green MA, Mathias CJ, Tong Y, Yong C, Boris RS, Brocken E, Hutchins GD, Sims JB, Hill DV, Smith N, Ferari C, Love H, Koch MO
doi: 10.1097/JU.0000000000004032
Further Publications Urology
Infectious complications following transperineal prostate biopsy with or without periprocedural antibiotic prophylaxis-a systematic review including meta-analysis of all comparative studies
Prostate Cancer Prostatic Dis
Wolff I, Büchner M, Hauner K, Wagenlehner F, Burchardt M, Abele-Horn M, Wullich B, Gilfrich C, Pilatz A, May M
doi: 10.1038/s41391-024-00934-9